These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9151342)

  • 21. Current dilemmas in the management of inflammatory bowel disease.
    Rutgeerts P
    Eur J Surg Suppl; 2002; (587):58-61. PubMed ID: 16144202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological therapies for treatment of chronic inflammatory bowel diseases. Status update].
    Metzler J; Stange EF
    Med Klin (Munich); 2002 May; 97(5):290-7. PubMed ID: 12078390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of the antibody response.
    Falchuk KR; Isselbacher KJ
    Gastroenterology; 1976 Jan; 70(1):5-8. PubMed ID: 1245283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Crohn's Disease - New Therapies].
    Klag T; Wehkamp J
    Dtsch Med Wochenschr; 2018 Jul; 113(13):953-959. PubMed ID: 29972839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-TNF antibodies in the treatment of intestinal inflammatory disease].
    Hinojosa J
    Gastroenterol Hepatol; 2000 May; 23(5):250-7. PubMed ID: 10902280
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V; Piepoli A; Perri F; Lombardi G; Latiano A; Napolitano G; Corritore G; Vandewalle P; Poulain D; Colombel JF; Andriulli A
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1143-52. PubMed ID: 15569117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P;
    Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-neutrophil cytoplasmic antibodies in Brazilian patients with inflammatory bowel disease.
    Cabral VL; Miszputen SJ; Catapani WR
    Hepatogastroenterology; 2003; 50(50):412-5. PubMed ID: 12749235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations in serum anti-alpha-galactosyl antibodies in patients with Crohn's disease and ulcerative colitis.
    D'Alessandro M; Mariani P; Lomanto D; Bachetoni A; Speranza V
    Clin Immunol; 2002 Apr; 103(1):63-8. PubMed ID: 11987986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis.
    Egan LJ; Sandborn WJ
    Curr Gastroenterol Rep; 2005 Dec; 7(6):485-91. PubMed ID: 16313879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.
    Levine DS; Fischer SH; Christie DL; Haggitt RC; Ochs HD
    Am J Gastroenterol; 1992 Jan; 87(1):91-100. PubMed ID: 1728132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytokine targetting therapy for inflammatory bowel diseases].
    Matsumoto T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1781-6. PubMed ID: 17037315
    [No Abstract]   [Full Text] [Related]  

  • 35. [Follow-up study of the development of autoantibodies in patients with chronic inflammatory bowel disease under anti-CD4 therapy].
    Buchwald S; Emmrich J; Seyfarth M; Emmrich F
    Immun Infekt; 1993 Apr; 21 Suppl 1():34-5. PubMed ID: 8344685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis.
    Seegers D; Bouma G; Peña AS
    Aliment Pharmacol Ther; 2002 Jul; 16 Suppl 4():53-8. PubMed ID: 12047261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological therapies for inflammatory bowel diseases.
    Rutgeerts P; Vermeire S; Van Assche G
    Gastroenterology; 2009 Apr; 136(4):1182-97. PubMed ID: 19249397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunopathology of ulcerative colitis and Crohn's disease, nonsurgical therapeutic considerations.
    Bläker F; Schäfer KH
    Eur J Pediatr; 1982 Nov; 139(3):162-4. PubMed ID: 6130950
    [No Abstract]   [Full Text] [Related]  

  • 39. Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. 21-15 May 2006, Los Angeles, CA, USA.
    Aylett P
    IDrugs; 2006 Jul; 9(7):452-4. PubMed ID: 16821150
    [No Abstract]   [Full Text] [Related]  

  • 40. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease.
    Schmidt C; Marth T; Wittig BM; Hombach A; Abken H; Stallmach A
    Pathobiology; 2002-2003; 70(3):177-83. PubMed ID: 12571423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.